Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUQUITAS phase III trial in metastatic oeso-gastric adenocarcinoma
2025-522395-92-00Phase 3Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Lonsurf + Fruzaqla with Lonsurf alone (2 arms). Primary endpoint: Overall survival. Planned start Dec 2025; status: authorised.
02
Drugs
trifluridine + tipiracilfruquintinib
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2025-522395-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522395-92-00.